
|Articles|April 24, 2004
Genentech enrolling patients for Lucentis clinical trial
Genentech, South San Francisco, CA, announced that the biotechnologycompany is enrolling patients into a Phase III clinical trial for its age-relatedmacular degeneration (AMD) drug Lucentis (ranibizumab, rhuFab V2).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Phase 3 NORTHSTAR Trial Launches for Gildeuretinol in Stargardt Disease
2
Rising Star: Introducing Viha Vig, MBChB
3
Self-Screening for Ocular Surface Malignancies Using a Smartphone
4
Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ)
5





















